Mateon Therapeutics (MATN) & The Competition Financial Survey
Mateon Therapeutics (NASDAQ: MATN) is one of 93 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Mateon Therapeutics to similar businesses based on the strength of its risk, profitability, institutional ownership, analyst recommendations, earnings, dividends and valuation.
Institutional & Insider Ownership
8.6% of Mateon Therapeutics shares are owned by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 2.3% of Mateon Therapeutics shares are owned by company insiders. Comparatively, 19.6% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a breakdown of recent recommendations and price targets for Mateon Therapeutics and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Mateon Therapeutics Competitors||164||547||1210||16||2.56|
Mateon Therapeutics presently has a consensus price target of $2.00, suggesting a potential upside of 326.98%. As a group, “Biotechnology” companies have a potential upside of 56.69%. Given Mateon Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Mateon Therapeutics is more favorable than its competitors.
This table compares Mateon Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Mateon Therapeutics Competitors||-919.42%||-189.81%||-26.55%|
Volatility and Risk
Mateon Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Mateon Therapeutics’ competitors have a beta of 1.14, suggesting that their average stock price is 14% more volatile than the S&P 500.
Valuation & Earnings
This table compares Mateon Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Mateon Therapeutics||N/A||-$14.59 million||-0.87|
|Mateon Therapeutics Competitors||$223.74 million||$57.84 million||-0.69|
Mateon Therapeutics’ competitors have higher revenue and earnings than Mateon Therapeutics. Mateon Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Mateon Therapeutics competitors beat Mateon Therapeutics on 7 of the 12 factors compared.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.
Receive News & Ratings for Mateon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.